Trial Profile
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2019
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Corcept Therapeutics
- 26 Jul 2019 Status changed from recruiting to discontinued.
- 29 Dec 2017 New trial record